GlassScriptPhysician profile
Louis B Cady
NPI 1053454413
$134,718.63
in general payments reported to CMS, 2019-2025
42 companies · $4,856 in 2025
The $4,856 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $15K · 2021: $8,363 · 2022: $34K · 2023: $33K · 2024: $15K · 2025: $4,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $9,150 · Travel and Lodging: $4,939 · Food and Beverage: $4,698 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $21,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,625.00 |
| Consulting Fee | $9,150.00 |
| Travel and Lodging | $4,938.56 |
| Food and Beverage | $4,698.36 |
| Education | $153.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $56,275.18 | 2021-2025 | Azstarys, Azstarys |
| Tris Pharma INC | $25,565.95 | 2020-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Ironshore Pharmaceuticals INC. | $24,205.76 | 2019-2023 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $16,345.64 | 2019-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $5,035.30 | 2021-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $1,118.02 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $734.30 | 2020-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $627.83 | 2019-2025 | |
| Almatica Pharma LLC | $541.98 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Alkermes, INC. | $541.91 | 2022-2025 | Lybalvi, Aristada |
| Harmony Biosciences LLC | $373.97 | 2020-2024 | Wakix |
| Neurocrine Biosciences, INC. | $346.02 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $325.83 | 2019-2025 | Spravato |
| Abbvie INC. | $323.64 | 2021-2024 | Vraylar |
| Allergan, INC. | $309.06 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Cady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.